R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 Riedell, 2018, Double hit and double expressors in lymphoma: definition and treatment, Cancer, 124, 4622, 10.1002/cncr.31646 Green, 2012, Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, 30, 3460, 10.1200/JCO.2011.41.4342 Johnson, 2012, Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol, 30, 3452, 10.1200/JCO.2011.41.0985 Horn, 2013, MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma, Blood, 121, 2253, 10.1182/blood-2012-06-435842 Hu, 2013, MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program, Blood, 121, 4021, 10.1182/blood-2012-10-460063 Alexandra, 2013, MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Haematologica, 98, 1554, 10.3324/haematol.2013.086173 Perry, 2014, MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab, Br J Haematol, 165, 382, 10.1111/bjh.12763 Staiger, 2017, clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large b-cell lymphoma treated within prospective clinical trials of the german high-grade non-hodgkin's lymphoma study group, J Clin Oncol, 35, 2515, 10.1200/JCO.2016.70.3660 Sehn, 2021, Diffuse large B-Cell lymphoma, N Engl J Med, 384, 842, 10.1056/NEJMra2027612 Zelenetz, 2021, NCCN Guidelines® insights: b-cell lymphomas, version 5.2021: featured updates to the nccn guidelines, J Natl Compr Canc Netw, 19, 1218, 10.6004/jnccn.2021.0054 Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin's lymphoma, N Engl J Med, 333, 1540, 10.1056/NEJM199512073332305 Herrera, 2017, Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation, J Clin Oncol, 35, 24, 10.1200/JCO.2016.68.2740 Bartlett, 2019, Dose-adjusted epoch-r compared with r-chop as frontline therapy for diffuse large b-cell lymphoma: clinical outcomes of the phase iii intergroup trial alliance/calgb 50303, J Clin Oncol, 37, 1790, 10.1200/JCO.18.01994 Aggarwal, 2016, Outcome of patients with Double-Expressor Lymphomas (DELs) treated with R-CHOP or DA-EPOCH-R, Blood, 128, 5396, 10.1182/blood.V128.22.5396.5396 Zhang, 2019, DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma, J Cancer Res Clin Oncol, 145, 117, 10.1007/s00432-018-2771-9 Dodero, 2019, Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma, Leukemia, 33, 1047, 10.1038/s41375-018-0320-9 Hardefeldt, 2019, Dose Adjusted DA-EPOCH-R does not improve outcomes in high grade b cell lymphoma with double expressor status or gain of MYC/BCL2, Blood, 134, 5336, 10.1182/blood-2019-125154 D'Angelo, 2021, Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: a multi-center analysis, Hematol Oncol, 39, 473, 10.1002/hon.2902 Devi, 2021, Outcomes of patients with double/triple expressor diffuse large b-cell lymphoma (dlbcl) treated with r-da-epoch/r-chop: a single-center experience, Leuk Res Rep, 16 Hans, 2004, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, 103, 275, 10.1182/blood-2003-05-1545 Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800 The R Project for Statistical Computing. 2021, Available at: https://www.r-project.org/. Accessed December 4. Vandermeer, 2015, Poor Outcomes among patients failing dose-adjusted EPOCH in aggressive lymphoma: a collaborative, retrospective study, Blood, 126, 1518, 10.1182/blood.V126.23.1518.1518 Ayers, 2020, Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure, Cancer, 126, 293, 10.1002/cncr.32526 Wilson, 2002, Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy, Blood, 99, 2685, 10.1182/blood.V99.8.2685 Dodero, 2022, Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome, Haematologica, 107, 1153, 10.3324/haematol.2021.278638 Pedersen, 2017, Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers, PLoS One, 12, 10.1371/journal.pone.0186983 Roh, 2021, BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis, Modern Pathology, 12, 1 Maurer, 2014, Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy, J Clin Oncol, 32, 1066, 10.1200/JCO.2013.51.5866 Dunleavy, 2013, Dose-adjusted epoch-rituximab therapy in primary mediastinal b-cell lymphoma, N Engl J Med, 368, 1408, 10.1056/NEJMoa1214561 Dunleavy, 2006, Primary Mediastinal Large B-Cell Lymphoma (pmbl) outcome may be significantly improved by the addition of rituximab to dose-adjusted (da)-epoch and obviates the need for radiation: results from a prospective study of 44 patients, Blood, 108, 209, 10.1182/blood.V108.11.209.209 Dunleavy, 2018, Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study, Lancet Haematol, 5, e609, 10.1016/S2352-3026(18)30177-7 Stepanishyna, 2020, DA-EPOCH-R VS R-CHOP in patients with primary mediastinal large b-cell lymphoma: results of prospective randomized Ukrainian multicenter study, Blood, 136, 9, 10.1182/blood-2020-141348 Burke, 2021, Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal b-cell lymphoma: a multicenter phase II trial, J Clin Oncol, 39, 3716, 10.1200/JCO.21.00920 Roschewski, 2020, Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma, J Clin Oncol, 38, 2519, 10.1200/JCO.20.00303 Miyazaki, 2019, DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study, Haematologica, 105, 2308, 10.3324/haematol.2019.231076 Pejša, 2017, Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients, Croat Med J, 58, 40, 10.3325/cmj.2017.58.40 Wilson, 2008, Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers, J Clin Oncol, 26, 2717, 10.1200/JCO.2007.13.1391 Purroy, 2015, Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group, Br J Haematol, 169, 188, 10.1111/bjh.13273 Wyndham, 2012, A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype, Haematologica, 97, 758, 10.3324/haematol.2011.056531 Gutierrez, 2000, Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH, J Clin Oncol, 18, 3633, 10.1200/JCO.2000.18.21.3633 Weis, 2019, Dosing vincristine in dose-adjusted EPOCH-R: to cap or not to cap?, J Clin Oncol, 37, 2952, 10.1200/JCO.19.01259